Non-small Cell Lung Cancer Treatment Market Segmentation:
Distribution Channel Segment Analysis
The hospital pharmacies are anticipated to grow by 56% in 2035. As per the study of the Centers for Disease Control and Prevention, more than 75% of the immunotherapy is infused under the hospital infrastructure setup. This increases the demand for hospital pharmacies as a distribution channel in the non-small cell lung cancer treatment market. Apart from that, fast claim for reimbursement is initiated under hospital pharmacies that create a way for higher accessibility for the patients.
Treatment Type Segment Analysis
The immunotherapy segment possesses high performance ability in the non-small cell lung cancer treatment market with a 42.5% share. Approval conducted by the Food and Drug Administration for the combo therapy ensures better patient outcomes. The combo therapy includes the assimilation of pembrolizumab and chemotherapy, which enriched the functioning of immunotherapy in the concerned market. Expansion of Medicare coverage for immunotherapy is expanded according to the reporting of the Centers for Medicare & Medicaid Services, which raised accessibility of the market.
Therapy Line Segment Analysis
Currently, first-line therapy is the largest segment of the non-small cell lung cancer treatment market. This is because it represents the first step in treatment, as it often involves the majority of patients diagnosed and treated. Recent developments in the field and with immunotherapy and many emerging biomarker-targeted therapies have significantly changed first-line therapy and have greatly improved the survival and response rates. Guidelines are increasingly recommending that non-small cell lung cancer patients undergo biomarker testing before starting therapy so that more patients can be appropriately stratified for first-line treatment. Clinical advances and guidelines are also important because insurance payers and health systems are focused on first-line interventions that can improve outcomes sooner rather than later.
Our in-depth analysis of the non-small cell lung cancer treatment market includes the following segments:
|
Segments |
Subsegments |
|
Therapy Type |
|
|
Distribution Channel |
|
|
Therapy Line |
|
